Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis.

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  G. Biondi-Zoccai,et al.  A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design. , 2016, American heart journal.

[3]  J. Sadowski,et al.  [Experience in application of therapies VA ECMO as short-term mechanical support of circulatory system of adult patients in cardiogenic shock]. , 2016 .

[4]  J. Sadowski,et al.  Veno-arterial extracorporeal membrane oxygenation for short-term mechanical circulation support in adults with cardiogenic shock: a single centre experience. , 2016, Kardiologia polska.

[5]  A. Markowitz,et al.  Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta‐analysis , 2015, Journal of cardiac surgery.

[6]  A. Zangrillo,et al.  A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. , 2015, British journal of anaesthesia.

[7]  J. Zijlstra,et al.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis , 2015, Intensive Care Medicine.

[8]  D. Carino,et al.  Levosimendan May Improve Weaning Outcomesin Venoarterial ECMO Patients , 2013, ASAIO journal.

[9]  I. Katsytadze,et al.  Long term effects of Levosimendan therapy in patients with cardiogenic shock , 2013 .

[10]  J. Vincent,et al.  Levosimendan for the treatment of subarachnoid hemorrhage-related cardiogenic shock , 2013, Intensive Care Medicine.

[11]  G. Andersen,et al.  Levosimendan in acute heart failure following primary percutaneous coronary intervention‐treated acute ST‐elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo‐controlled study , 2013, European journal of heart failure.

[12]  F. Fedele,et al.  HEMODYNAMIC IMPROVEMENT FOLLOWING LEVOSIMENDAN TREATMENT IN ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK PATIENTS TREATED WITH PRIMARY PCI AND IABP , 2013 .

[13]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[14]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[15]  Lu-qing Wei,et al.  Continuous levosimendan infusion for refractory cardiogenic shock complicating severe acute dichlorvos poisoning. , 2012, The American journal of the medical sciences.

[16]  J. Borén,et al.  Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction , 2010, Vascular health and risk management.

[17]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[18]  G. Stazi,et al.  Efficacy of levosimendan in Takotsubo‐related cardiogenic shock , 2010, Acta anaesthesiologica Scandinavica.

[19]  K. Werdan,et al.  Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan* , 2009, Critical care medicine.

[20]  B. Merkely,et al.  Levosimendan therapy does not improve survival of post-resuscitation cardiogenic shock patients , 2009, Critical Care.

[21]  A. Domínguez-Rodríguez,et al.  Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. , 2008, International journal of cardiology.

[22]  R. Strasser,et al.  Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction* , 2008, Critical care medicine.

[23]  A. Domínguez-Rodríguez,et al.  Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. , 2008, International journal of cardiology.

[24]  K. Werdan,et al.  Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction , 2008, Acute cardiac care.

[25]  C. Reithmann,et al.  Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction , 2008, Acute cardiac care.

[26]  K. Werdan,et al.  Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock * , 2007, Critical care medicine.

[27]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[28]  W. Toller,et al.  Levosimendan, a New Inotropic and Vasodilator Agent , 2006, Anesthesiology.

[29]  D. Kass,et al.  Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart , 2006, Circulation.

[30]  R. Rokyta,et al.  The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. , 2006, Neuro endocrinology letters.

[31]  K. Csapo,et al.  Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. , 2006, Cardiovascular drug reviews.

[32]  J. Alhashemi.  Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. , 2005, British journal of anaesthesia.

[33]  R. Solaro,et al.  The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitiser, with cardiac troponin c , 2004, Molecular and Cellular Biochemistry.

[34]  J. Boldt,et al.  Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[35]  P. Kaheinen,et al.  Effects of Levosimendan and Milrinone on Oxygen Consumption in Isolated Guinea-Pig Heart , 2004, Journal of cardiovascular pharmacology.

[36]  M. Nalos,et al.  Efficacy of levosimendan in shock , 2004, Critical Care.

[37]  G. Castro,et al.  1088-125 Levosimendan is safe and effective in patients with severe low cardiac output heart failure and critical hypotension , 2004 .

[38]  G. Karth,et al.  Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines , 2003, Acta anaesthesiologica Scandinavica.

[39]  H. Iida,et al.  Myocardial efficiency during levosimendan infusion in congestive heart failure , 2000, Clinical pharmacology and therapeutics.

[40]  G. Hasenfuss,et al.  Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. , 1998, Circulation.

[41]  J. Murín,et al.  [Cardiogenic shock in acute myocardial infarct]. , 1997, Vnitrni lekarstvi.

[42]  K. Någren,et al.  Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers , 1997, Clinical pharmacology and therapeutics.